U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 400 points on Tuesday.
The Dow traded down 0.97% to 40,818.82 while...
On May 6, 2025, Piper Sandler analyst Adam Maeder issued a rating change for Tactile Systems Tech (TCMD), downgrading the stock from "Overweight" to "Neutral".
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 250 points on Tuesday.
The Dow traded down 0.69% to 40,932.59 while the NASDA...
California-based Marin Software Incorporated (MRIN) is up over 141 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.
Analyst Adam Maeder from Piper Sandler has downgraded Tactile Systems (TCMD) from Overweight to Neutral, adjusting the price target from $25 to $14. This decisi
Total Revenue: Increased 0.3% year over year to $61.3 million.Lymphedema Revenue: Decreased 3% year over year to $50.6 million.Airway Clearance Revenue: Increa
May 05, 2025 / 09:00PM GMTOperator Welcome, ladies and gentlemen, to the first-quarter 2025 earnings conference call for Tactile Medical. (Operator Instructions
MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (”Tactile Medical”; the ”Company”) ( TCMD), a medical technology compan
Revenue: $61.3 million, slightly below the estimated $63.28 million, marking a 0.3% increase year-over-year.Gross Margin: Improved to 74% from 71% in Q1 2024,
Tactile Medical (TCMD) reported its first-quarter revenue at $61.27 million, falling short of the consensus estimate of $63.48 million. Despite this revenue mis
On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Tactile Systems Technology Inc. (NASDAQ: TCMD), reducing its
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...
Total Revenue: $293 million for the full year, 6.8% growth year over year; $85.6 million in Q4, 10.2% growth year over year.Lymphedema Product Sales: $77.1 mil
Feb 18, 2025 / 10:00PM GMTOperator Please stand by. Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2024 earnings conference call for Tacti
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 21.21% and 0.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?